Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Review of Abortion Pill Postponed amid Flock of Public Comments
March 24, 2023
- Xocova to Be Commercially Available from March 31
March 24, 2023
- Additional Safety Measures for Xocova “Not Needed at This Time”: MHLW Panel
March 24, 2023
- MHLW Orders Label Revisions for TB Drugs, Steboronine
March 24, 2023
- Japan to Designate 3 More Diseases as Intractable Illnesses
March 24, 2023
- MHLW Panel Begins Discussions on Revision of Basic Policy for Blood Products
March 23, 2023
- Generic Dispensing Tops 82%; 57% of Pharmacies Not Active on Biosimilars: Poll
March 23, 2023
- Chuikyo’s SaMD Working Group to Compile Opinion by July
March 23, 2023
- Majority of Pharmacists Think Setting Up Integrated Drug Supply Website Is Vital: MHLW Study
March 22, 2023
- Japan to Tap Patient-Initiated Mixed Care Scheme for Pediatric Cancer Meds
March 22, 2023
- MHLW Council Discusses Root Causes of Drug Supply Disruptions, Yakkasa Issues
March 22, 2023
- MHLW Panel OKs 184 More Health Damage Claims for COVID-19 Jabs
March 22, 2023
- Japan Approves J-TEC’s Cell Sheet for Vitiligo, Aurion’s Bullous Keratopathy Therapy
March 22, 2023
- Oral Abortion Pill Mefeego Up for Another Round of Panel Reviews on March 24
March 20, 2023
- Expert Panel Discusses 2% Buffer Zone, Member Floats “Regional Index”
March 20, 2023
- Expert Panel Seeks Revision of Drug Pricing Rules to Stabilize Supplies
March 20, 2023
- Expert Panel Talks over Yakkasa, Revamp of Price Revision Method; Fixed Margin, Claw-Back Mooted
March 20, 2023
- 97 Health Damages Reported for Kymriah in Japan: April-September
March 17, 2023
- Japan to Add Purchased Doses of Paxlovid, Xocova to Govt Stockpile
March 17, 2023
- Health Minister Vows to Make Use of Govt-Purchased Xocova
March 17, 2023
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…